**Guiding the Future of Drug Development**

Resverlogix is a global leader in developing epigenetic therapies to improve the health and well-being of people suffering from chronic illnesses.

By harnessing the ability of epigenetic therapies to correct flawed signals within our cells, we can effectively regulate the expression of disease-causing genes.

---

**Apabetalone: Designed to Regulate Gene Expression**

**Robust Intellectual Property Protection (to 2040)**

**FDA Breakthrough Therapy Designation**

**40+ peer-reviewed publications (incl. Cell, Nature)**

**4200+ patient-years of FDA-reviewed safety data**

**Detailed proteomic & transcriptomic analyses**

---

**Apabetalone: De-risked Asset with a Track Record of Safety and Efficacy**

**Without Altering DNA**

Apabetalone regulates expression of disease-causing genes.

**Epigenetic Mechanism**

Through inhibition of BET proteins, apabetalone acts at the level of gene transcription.

**Acting Upstream**

Conventional pharmaceuticals target single proteins, while apabetalone can benefit multiple dysregulated pathways.

---

**Breakthrough Therapy Designation**

Apabetalone is the first therapy of its kind to receive breakthrough therapy designation from the US Food and Drug Administration for high-risk cardiovascular disease.

---

**Without Altering DNA**

Apabetalone regulates expression of disease-causing genes.

**Epigenetic Mechanism**

Through inhibition of BET proteins, apabetalone acts at the level of gene transcription.

**Acting Upstream**

Conventional pharmaceuticals target single proteins, while apabetalone can benefit multiple dysregulated pathways.
## Indication

<table>
<thead>
<tr>
<th></th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
</table>
| **High-Risk CVD**  
Type 2 Diabetes Mellitus, Low HDL-C, and Recent ACS |          | ASSERT [2b]  
SUSTAIN [2b]  
ASSURE [2b] | BETonMACE  
(Completed)  
BETonMACE2 (Ready) |
| **High-Risk CKD**  
Type 2 Diabetes Mellitus, CVD, and CKD |          |         | BETonCKD (Ready)     |
| **Post COVID-19 Conditions** |          |         | Phase2/3  
(Planned) |
| **PAH** | APPRoAcH-p  
(Completed) | APPRoAcH-2  
(Planned) |         |
| **Vascular Dementia** |          |         | BETonMACE  
(Subgroup) |

**Combined Patient-years of Safety**: 4200

---

## Recent Updates

- **September 28, 2022**  
  Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
- **August 22, 2022**  
  Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
- **August 15, 2022**  
  Resverlogix Announces Appointment of New Chief Scientific Officer

---

## Our Management Team

- **Donald J. McCaffrey**  
  President & Chief Executive Officer  
  Co-Founder
- **Dr Ewelina Kulikowski**  
  PhD  
  Chief Scientific Officer
- **Dr Michael Sweeney**  
  MD  
  SVP, Clinical Development
- **Dr Jan O. Johansson**  
  MD, PhD  
  SVP, Medical Affairs
- **Dr Henrik C. Hansen**  
  PhD  
  VP, Intellectual Property
- **Dr Ravi Jahagirdar**  
  DVM, MS  
  VP, Pharmacology, Toxicology & Safety
- **Brad Cann**  
  CPA, CA, CBV  
  Chief Financial Officer

---

## Contact Information

- **ir@resverlogix.com**
- **403 254 9252**

---

## Follow Us

- **@Resverlogix_RVX**
- **linkedin.com/company/resverlogix-corp/**